How to buy Burning Rock Biotech (BNR) stock

Burning Rock Biotech Limited is a diagnostics & research business based in the US. Burning Rock Biotech shares (BNR) are listed on the NASDAQ and all prices are listed in US Dollars. Burning Rock Biotech employs 938 staff and has a trailing 12-month revenue of around 0.00.

Burning Rock Biotech stock price (NASDAQ: BNR)

Use our graph to track the performance of BNR stocks over time.

Burning Rock Biotech shares at a glance

• Key figures

Information last updated 2021-07-15.

Latest market close	$27.07
52-week range	$18.64 - $39.75
50-day moving average	$28.26
200-day moving average	$29.64
Wall St. target price	$38.30
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.48

Buy Burning Rock Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Burning Rock Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Burning Rock Biotech Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Burning Rock Biotech price performance over time

Historical closes compared with the close of $27.07 from 2021-05-28

1 week (2021-07-12)	N/A
1 month (2021-06-23)	-4.82%
3 months (2021-04-19)	N/A
6 months (2021-01-19)	N/A

1 year (2020-07-19)	N/A
2 years (2019-07-19)	N/A
3 years (2018-07-19)	N/A
5 years (2016-07-19)	N/A

Burning Rock Biotech financials

Revenue TTM	$469.2 million
Gross profit TTM	$313.9 million
Return on assets TTM	-17.49%
Return on equity TTM	-32.65%
Profit margin	-112.12%
Book value	N/A
Market capitalisation	$2.8 billion

TTM: trailing 12 months

Shorting Burning Rock Biotech shares

There are currently 1.4 million Burning Rock Biotech shares held short by investors – that's known as Burning Rock Biotech's "short interest". This figure is 5.5% down from 1.5 million last month.

There are a few different ways that this level of interest in shorting Burning Rock Biotech shares can be evaluated.

Burning Rock Biotech's "short interest ratio" (SIR)

Burning Rock Biotech's "short interest ratio" (SIR) is the quantity of Burning Rock Biotech shares currently shorted divided by the average quantity of Burning Rock Biotech shares traded daily (recently around 289223.34710744). Burning Rock Biotech's SIR currently stands at 4.84. In other words for every 100,000 Burning Rock Biotech shares traded daily on the market, roughly 4840 shares are currently held short.

However Burning Rock Biotech's short interest can also be evaluated against the total number of Burning Rock Biotech shares, or, against the total number of tradable Burning Rock Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Burning Rock Biotech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Burning Rock Biotech shares in existence, roughly 10 shares are currently held short) or 0.0334% of the tradable shares (for every 100,000 tradable Burning Rock Biotech shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Burning Rock Biotech.

Find out more about how you can short Burning Rock Biotech stock.

Burning Rock Biotech share dividends

We're not expecting Burning Rock Biotech to pay a dividend over the next 12 months.

Have Burning Rock Biotech's shares ever split?

Burning Rock Biotech's shares were split on a 1:3 basis on 31 July 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Burning Rock Biotech shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Burning Rock Biotech shares which in turn could have impacted Burning Rock Biotech's share price.

Burning Rock Biotech overview

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene.

Frequently asked questions

What percentage of Burning Rock Biotech is owned by insiders or institutions?
Currently 0.114% of Burning Rock Biotech shares are held by insiders and 41.557% by institutions. How many people work for Burning Rock Biotech?
Latest data suggests 938 work at Burning Rock Biotech. When does the fiscal year end for Burning Rock Biotech?
Burning Rock Biotech's fiscal year ends in December. Where is Burning Rock Biotech based?
Burning Rock Biotech's address is: Building 3, Standard Industrial Unit 2, Guangzhou, China, 510005 What is Burning Rock Biotech's ISIN number?
Burning Rock Biotech's international securities identification number is: US12233L1070